Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
2009年1月19日 - 11:00PM
PRニュース・ワイアー (英語)
Latest Waiver Covers Cartridges For 6+, E3+, EC4+, Creatinine and
Glucose PRINCETON, N.J., Jan. 19 /PRNewswire-FirstCall/ -- Abbott
announced today that the U.S. Food and Drug Administration (FDA)
has granted waived status under the Clinical Laboratory Improvement
Amendments of 1988 (CLIA) for five additional test cartridges used
by its i-STAT handheld blood analyzer. Cartridges for E3+, EC4+ and
6+ aid the clinician in assessing a patient's metabolic state
within a few minutes. The glucose cartridge quickly delivers a
patient's diagnostic blood glucose level. Creatinine is a measure
and indicator of a patient's renal function right at the patient's
side. The five are components of the CHEM8+ cartridge, which the
FDA waived in 2007. The CHEM8+ cartridge allows a clinician to run
a basic chemistry panel on a patient together with hemoglobin and
hematocrit tests. Waived status makes these tests more widely
available for use beyond the hospital setting, for example in a
physician's office or outpatient clinic. "These additional CLIA
waivers underscore the high quality and reliability of i-STAT
cartridge technology and expand its potential beyond the hospital
setting," said Greg Arnsdorff, vice president, point of care
diagnostics, Abbott. "As these tests now become increasingly
available in physicians' offices, more physicians will be able to
provide their patients with treatment options in one visit, thereby
improving the quality of care and eliminating the cost and hassle
of a second appointment. " The CLIA waivers indicate that these
test cartridges are simple and accurate and can be made more
broadly available to healthcare providers where fast results are
needed such as physicians' offices, outpatient clinics, imaging
centers, catheterization labs, as well as emergency departments,
intensive care units, operating rooms, and military bases. By
providing these critical test results rapidly, health care
providers can quickly monitor and effectively manage their
patients' care. The i-STAT(R) System The i-STAT System accelerates
the availability of critical test information that clinicians
require to make rapid triage and treatment decisions when
diagnosing a patient's condition or monitoring a patient's
treatment response. Weighing only 18 ounces, the i-STAT System is
an easy-to- use handheld analyzer capable of providing
time-sensitive test results at the patient's side in just minutes.
To perform a test, the user places two or three drops of whole
blood on the test cartridge, which is then inserted into the
analyzer. A new test cartridge is used for each patient. Utilizing
test- specific cartridges that are fully self-contained, the i-STAT
System delivers lab-accurate testing for blood gases, electrolytes,
chemistries, coagulation, hematology, glucose and cardiac markers.
i-STAT is at the forefront of expanding the possibilities with the
industry's most comprehensive panel of bedside tests on a single
platform. The i-STAT System is currently used in more than 1,800
hospitals where rapid test results are critical for better patient
care. The system is used in emergency departments, intensive care
units, operating rooms, as well as catheterization laboratories,
outpatient clinics and physician offices. About Abbott Point of
Care Abbott Point of Care, headquartered in Princeton, NJ,
develops, manufactures and markets critical medical diagnostic and
data management products for rapid blood analysis. The company's
premier product is the i- STAT, a market-leading handheld blood
analyzer capable of performing a panel of commonly ordered blood
tests on two or three drops of blood at the patient's side.
(http://www.abbottpointofcare.com/) About Abbott Abbott is a
global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics.
The company employs more than 68,000 people and markets its
products in more than 130 countries. Abbott's news releases and
other information are available on the company's Web site at
http://www.abbott.com/. DATASOURCE: Abbott CONTACT: Media, Don
Braakman, +1-847-937-0080, or Financial, Tina Ventura,
+1-847-935-9390, both of Abbott Web site: http://www.abbott.com/
http://www.abbottpointofcare.com/
Copyright